Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)
General Information of Drug (ID: DR2012) | ||||||
---|---|---|---|---|---|---|
Drug Name |
Dihydrocoumarin
|
|||||
Synonyms |
Benzodihydropyrone; Benzopyranone, dihydro-; Chroman, 2-oxo-; Coumarin, 3,4-dihydro-; Dihydrobenzopyrone; Melilotic acid lactone; Melilotine; Meliotine; Oxochroman; Usaf do-12; chroman-2-one; dihydrocoumarin; hydrocoumarin; melilotic lactone; melilotin; melilotol; 1,2-benzodihydropyrone; 119-84-6; 2-Hydroxydihydrocinnamic acid lactone; 2-chromanone; 2H-1-Benzopyran-2-one, 3,4-dihydro-; 3,4-Dihydro-2H-1-benzopyran-2-one; 3,4-Dyhydrocoumarin; 3,4-dihydro-2H-chromen-2-one; 3,4-dihydrocoumarin; NCI-C55890
|
|||||
Indication | Discovery agent | Investigative | [1] | |||
Structure | ||||||
3D MOL | 2D MOL | |||||
Pharmaceutical Properties | Molecular Weight | 148.16 | Topological Polar Surface Area | 26.3 | ||
Heavy Atom Count | 11 | Rotatable Bond Count | 0 | |||
Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 2 | |||
Cross-matching ID | ||||||
The Metabolic Roadmap of This Drug | |||||
---|---|---|---|---|---|
The Full List of Drug Metabolites (DM) of This Drug | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
The Full List of Metabolic Reaction (MR) of This Drug | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||||||||||||||||||||
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Experimental Enzyme Kinetic Data of This Drug | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.